AC
DYN icon

Armistice Capital’s Dyne Therapeutics DYN Stock Holding History

Armistice Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.6M Sell
3,087,226
-87,884
-3% -$1.63M 0.84% 15
2026
Q1 		$57.6M Sell
3,175,110
-74,598
-2% -$1.29M 1.02% 14
2025
Q4 		$63.6M Buy
3,249,708
+185,708
+6% +$3.52M 0.76% 19
2025
Q3 		$38.8M Buy
3,064,000
+504,000
+20% +$5.75M 0.58% 27
2025
Q2 		$24.4M Sell
2,560,000
-208,000
-8% -$2.29M 0.42% 36
2025
Q1 		$29M Buy
2,768,000
+1,803,482
+187% +$25.8M 0.43% 47
2024
Q4 		$22.7M Sell
964,518
-190,686
-17% -$5.64M 0.31% 63
2024
Q3 		$41.5M Buy
1,155,204
+184,313
+19% +$7.34M 0.66% 30
2024
Q2 		$34.3M Sell
970,891
-29,109
-3% -$846K 0.43% 40
2024
Q1 		$28.4M Buy
1,000,000
+176,000
+21% +$3.98M 0.38% 43
2023
Q4 		$11M Sell
824,000
-376,000
-31% -$3.67M 0.15% 78
2023
Q3 		$10.8M Buy
1,200,000
+288,000
+32% +$3.1M 0.16% 83
2023
Q2 		$10.3M Buy
+912,000
New +$10.8M 0.15% 95

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital's DYN Position: Q2 2026 in Review

Armistice Capital reduced its Dyne Therapeutics (DYN) stake by 2.8% in Q2 2026, selling an estimated $1.63M and leaving 3,087,226 shares worth $68.6M. The position accounts for 0.84% of the portfolio, ranked #15.

Armistice Capital first reported a position in DYN in Q2 2023 and has held it in 13 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Armistice Capital held 3,087,226 shares of Dyne Therapeutics worth $68.6M as of Q2 2026.
  • Armistice Capital sold 87,884 Dyne Therapeutics shares in Q2 2026, an estimated $1.63M.
  • Dyne Therapeutics made up 0.84% of Armistice Capital's portfolio in Q2 2026, its #15 holding.
  • Armistice Capital first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.